Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus

PHASE2CompletedINTERVENTIONAL
Enrollment

547

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Placebo (low dose)

Placebo tablets once a day

DRUG

Placebo (low dose)

Placebo tablets once a day

DRUG

Placebo (mid dose)

Placebo tablets once a day

DRUG

Placebo (high dose)

Placebo tablets once a day

DRUG

BI 10773

BI 10773 tablets low dose once a day

DRUG

Placebo (mid dose)

Placebo tablets once a day

DRUG

Placebo (high dose)

Placebo tablets once a day

DRUG

Placebo (high dose)

Placebo tablets once a day

DRUG

BI 10773

BI 10773 tablets mid-high dose once a day

DRUG

BI 10773

BI 10773 tablets high dose once a day

DRUG

Placebo (mid dose)

Placebo tablets once a day

DRUG

Placebo (high dose)

Placebo tablets once a day

DRUG

Placebo (low dose)

Placebo tablets once a day

DRUG

Placebo (low dose)

Placebo tablets once a day

DRUG

BI 10773

BI 10773 tablets mid-low dose once a day

DRUG

Placebo (mid dose)

Placebo tablets once a day

Trial Locations (32)

Unknown

1245.38.016 Boehringer Ingelheim Investigational Site, Chiyoda-ku, Tokyo

1245.38.001 Boehringer Ingelheim Investigational Site, Chuo-ku, Tokyo

1245.38.003 Boehringer Ingelheim Investigational Site, Chuo-ku, Tokyo

1245.38.002 Boehringer Ingelheim Investigational Site, Hachioji, Tokyo

1245.38.010 Boehringer Ingelheim Investigational Site, Hanamaki, Iwate

1245.38.005 Boehringer Ingelheim Investigational Site, Kamakura, Kanagawa

1245.38.020 Boehringer Ingelheim Investigational Site, Kanazawa, Ishikawa

1245.38.013 Boehringer Ingelheim Investigational Site, Kashiwa, Chiba

1245.38.019 Boehringer Ingelheim Investigational Site, Katsushika-ku, Tokyo

1245.38.021 Boehringer Ingelheim Investigational Site, Kyoto, Kyoto

1245.38.024 Boehringer Ingelheim Investigational Site, Matsuyama, Ehime

1245.38.004 Boehringer Ingelheim Investigational Site, Minato-ku, Tokyo

1245.38.011 Boehringer Ingelheim Investigational Site, Moriya, Ibaraki

1245.38.030 Boehringer Ingelheim Investigational Site, Naha, Okinawa

1245.38.032 Boehringer Ingelheim Investigational Site, Okawa, Fukuoka

1245.38.031 Boehringer Ingelheim Investigational Site, Okinawa, Okinawa

1245.38.025 Boehringer Ingelheim Investigational Site, Saga, Saga

1245.38.014 Boehringer Ingelheim Investigational Site, Saitama, Saitama

1245.38.006 Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido

1245.38.007 Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido

1245.38.008 Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido

1245.38.009 Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido

1245.38.012 Boehringer Ingelheim Investigational Site, Sasima-gun, Ibaraki

1245.38.015 Boehringer Ingelheim Investigational Site, Shinjuku-ku, Tokyo

1245.38.018 Boehringer Ingelheim Investigational Site, Shinjuku-ku, Tokyo

1245.38.017 Boehringer Ingelheim Investigational Site, Suginami-ku, Tokyo

1245.38.022 Boehringer Ingelheim Investigational Site, Suita, Osaka

1245.38.023 Boehringer Ingelheim Investigational Site, Ube, Yamaguchi

1245.38.026 Boehringer Ingelheim Investigational Site, Urasoe, Okinawa

1245.38.027 Boehringer Ingelheim Investigational Site, Urasoe, Okinawa

1245.38.028 Boehringer Ingelheim Investigational Site, Urasoe, Okinawa

1245.38.029 Boehringer Ingelheim Investigational Site, Urasoe, Okinawa

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Boehringer Ingelheim

INDUSTRY